Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone versus cabergoline for OHSS prevention in women with PCOS undergoing ovarian stimulation
IRCT20250823066956N1Phase 2Completed
- Sponsor
- Islamic Azad University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian hyperstimulation syndrome (OHSS) comparing Cabergoline with Hydrocortisone (2 arms). Primary endpoint: Absence of ovarian hyperstimulation syndrome. Started Mar 2026; status: completed.
02
Drugs
hydrocortisonecabergoline
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on IRCT20250823066956N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250823066956N1.